KLRS Kalaris Therapeutics, Inc.
$3.95 +0.25%
Updated
Healthcare · Biological Products, (No Diagnostic Substances)
Kalaris Therapeutics, Inc. (KLRS) is a healthcare company in the Biological Products, (No Diagnostic Substances) industry, with a market capitalization of $94 million. Shares last traded at $3.95, 66.6% below their 52-week high. Over the past year the stock is down 10.0%.
Market Cap
$94M
Shares Out
23.8M
EPS (TTM)
$-5.70
P/E Ratio
—
P/S Ratio
569.88
P/B Ratio
1.63
Dividend / Share
—
Dividend Yield
—
52-Week High
$11.81
52-Week Low
$3.25
Volume
1,042
Avg Vol (3m)
7,450.032
Performance
1W
-5.05%
1M
-6.18%
3M
-15.69%
6M
-59.45%
YTD
-52.47%
1Y
-10.02%
Chart
Full chart →Daily candles · volume · SMA(20)/SMA(50) · Databento EQUS.MINI.
Technicals
RSI (14)
46.25
SMA (50)
$4.13
SMA (200)
$6.45
Price vs SMA50
-4.37%
Price vs SMA200
-38.78%
ATR (14)
$0.22
Financials
Revenue
$0M
Net Income
$-44M
Gross Margin
—
Operating Margin
—
Net Margin
—
Return on Equity
-76.7%
Return on Assets
-44.5%
Current Ratio
10.98
Debt / Equity
0.73
Revenue Growth (YoY)
—
Latest reported annual period ending 2026-06-30 · SEC EDGAR/XBRL.
Recent earnings
| Period | EPS (diluted) | Reported |
|---|---|---|
| Q2 2026 | $-0.94 | 2026-08-11 |
| Q1 2026 | $-0.46 | 2026-05-12 |
| FY 2025 | $-2.85 | 2026-03-17 |
| Q3 2025 | $-2.41 | 2025-11-12 |
| Q2 2026 | $-1.89 | 2026-08-11 |
| Q1 2026 | $-2.52 | 2026-05-12 |
Biological Products, (No Diagnostic Substances) peers
KLRS vs 14 industry peers (Biological Products, (No Diagnostic Substances)), by market cap. Updated
P/S vs peers
569.88 / 19.49 med
+2823% premium
1–14 of 14
| AMGN | Amgen | $240.1B | 27.47 | 6.30 | 23.0% | +0.31% |
| GILD | Gilead Sciences | $187.5B | -57.87 | 6.16 | -10.6% | +1.09% |
| MRNA | Moderna | $58.8B | -18.68 | — | — | -1.94% |
| RVMD | Revolution Medicines, Inc. | $45.2B | -25.55 | — | — | +0.76% |
| BIIB | Biogen | $33.1B | 24.16 | 3.34 | 13.8% | +0.78% |
| NBIX | Neurocrine Biosciences Inc | $16.1B | 22.81 | 4.77 | 20.9% | +0.33% |
| EXEL | Exelixis, Inc. | $14.7B | 17.03 | 6.02 | 35.3% | +1.00% |
| HALO | Halozyme Therapeutics, Inc. | $12.6B | 30.39 | 7.55 | 24.9% | +1.01% |
| TECH | Bio-Techne | $11.4B | 62.48 | 9.35 | 15.0% | +0.21% |
| KRYS | Krystal Biotech, Inc. | $11.0B | 45.52 | 24.95 | 54.8% | +0.58% |
| APGE | Apogee Therapeutics, Inc. | $10.2B | -34.57 | — | — | +0.04% |
| KYMR | Kymera Therapeutics, Inc. | $9.7B | -32.51 | — | — | -1.24% |
| RGEN | Repligen Corp | $9.6B | 230.53 | 12.20 | 5.3% | -1.87% |
| PCVX | Vaxcyte, Inc. | $9.1B | -8.56 | — | — | -0.62% |
Source: SEC EDGAR (fundamentals/EPS/dividends) · Databento EQUS.MINI (prices) · market cap & yield computed by tradmap. Informational only — not financial advice.